Reported 1 day ago
Citi analyst Geoff Meacham maintains a Buy rating for Gilead (GILD) with a $125 price target despite the FDA's clinical hold on its Phase 2 WONDERS trials due to safety concerns in participants. While this setback may delay the projected launch of the GS-1720/GS-4182 HIV treatment combination to 2029 or 2030, it does not affect ongoing HIV treatments and is seen as a minor hurdle. Citi remains optimistic about Gilead's future developments in HIV treatment.
Source: YAHOO